WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

A Sanofi subsidiary has claimed FDA approval for the first biosimilar ... which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

but will still have to Afrezza alongside long-acting (basal) insulin treatments such as Sanofi's Lantus. Despite the FDA approval, many analysts are sceptical about its chances in the highly ...

The US Food and Drug Administration approved the first-ever rapid-acting ... used insulin product Novolog (insulin aspart).

In a major breakthrough for diabetes treatment, scientists have found a new way to regenerate insulin-producing cells ... pancreatic duct cells to two FDA-approved drugs: GSK126 and Tazemetostat.

it's currently the only FDA-approved insulin inhaler. The Afrezza inhaler is much smaller than Exubera, with premeasured, rapid-acting insulin you use before meals. The makers of Afrezza say the ...

Tandem Diabetes Care shared that its Capillary Biomedical (CapBio) subsidiary won FDA 510(k) clearance for a new infusion set.

FDA first approved the biosimilar in June 2020 for ... the lowest available for a long-acting insulin glargine on the market." Then in July 2021, the agency upgraded Semglee's status to an ...

Shortly before the warning letter was lifted, Medtronic received FDA approval for its 780G insulin pump, which had been under review since 2021. At the time, analysts with RBC Capital Markets said ...

Cells meant to protect you start destroying insulin-producing ... Because the drug is already FDA-approved for psoriasis, researchers may be able to launch human trials faster than usual.

The submissions include an application for the MiniMed™ 780G pump as an alternate controller enabled (ACE) insulin ... regarding the FDA clearance will be disclosed upon approval.